Evaluation of the effect of interleukin-10 on the multiplication of Mycobacterium avium complex in human macrophages and in C57BL/6 mice  Hilte F. Geerdes-Fenge,

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents
Molecular evolution of Mycobacterium tuberculosis
L. Boyanova  Clinical Microbiology and Infection 
Gut bacterial microbiota and obesity
Approach to diagnosis of infective endocarditis
Clinical Microbiology and Infection
Evaluation of tumor necrosis factor-α, interleukin-6 and C-reactive protein plasma levels as predictors of bacteremia in patients presenting signs of.
Herpes zoster in non-hospitalized children
Hydatid disease Clinical Microbiology and Infection
E. Cambau, M. Drancourt  Clinical Microbiology and Infection 
Link between intracellular pathogens and cardiovascular diseases
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Surveillance of Legionnaires’ disease in Austria
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
Clinical Microbiology and Infection
In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species  Jacques Dubois, Claude St-Pierre  Clinical.
Impacts of interleukin-12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in mice  Nacer Lounis, Baohong Ji, Chantal Truffat-Pernot,
Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente  
Structure of grepafloxacin relative to activity and safety profile
Vector control: a cornerstone in the malaria elimination campaign
C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins
Sofie Arens, Jan Verhaegen, Ludo Verbist 
Training for the infectious diseases speciality in Norway
Cephalosporins: a pharmacological update
Epidemiology of opportunistic infections in AIDS patients
Laboratory diagnosis and biosafety issues of biological warfare agents
Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response.
Sepsis and neutropenia induced by clozapine
Gastrointestinal and respiratory Mycobacterium avium colonization and development of disseminated infection in HIV-positive patients  Giampietro Nardi,
Uncommon opportunistic fungi: new nosocomial threats
Levofloxacin in the treatment of ventilator-associated pneumonia
G. Pappas  Clinical Microbiology and Infection 
Metagenomics and probiotics
Advisory group on Home-based and Outpatient Care (AdHOC): an international consensus statement on non-inpatient parenteral therapy  D. Nathwani, J.-J.
Effect of antioxidants on the immune response of Helicobacter pylori
Laboratory diagnosis of Clostridium difficile disease
Recent developments in staphylococcal scalded skin syndrome
S8 – S47 and O50 – O440 Clinical Microbiology and Infection
Interactions between cytomegalovirus and the p53 tumor suppressor gene in atherosclerotic vascular disease  Inge O. Baas, G. Johan A. Offerhaus, Ralph.
A. Bryskier  Clinical Microbiology and Infection 
Community-acquired pneumonia: epidemiologic and clinical consideration
Training in infectious diseases and tropical medicine in Britain
Current experience in treating invasive zygomycosis with posaconazole
Reducing antibiotic use in influenza: challenges and rewards
Andrew M. Middleton, Maureen V. Chadwick, Harold Gaya 
Clinical infection services—the Leiden experience
Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party  Dilip Nathwani, Christopher Conlon  Clinical.
Training in infectious diseases—looking to the future
Statin use and clinical outcomes among pneumonia patients
European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis  Miles Denton, Kevin G Kerr, Fraser Lewis  Clinical.
Clinical Microbiology and Infection
Evaluation of the performance of the Helico Blot 2
Overview of cefixime use in community-acquired infections
Sanford Chodosh  Clinical Microbiology and Infection 
Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe  Robert D. Fox  Clinical Microbiology.
Abstracts Clinical Microbiology and Infection
Modelling during an emergency: the 2009 H1N1 influenza pandemic
New oral cephalosporins in pediatric community-acquired infections
Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group†   H. Goossens  Clinical.
J.L. Balcázar  Clinical Microbiology and Infection 
The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands  J.W. Mouton, A.R. Jansz  Clinical.
New patterns of HIV-1 resistance during HAART
J.A. Pérez-Molina, F. Fernández  Clinical Microbiology and Infection 
Impact of antibiotic restrictions: the patient's perspective
Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party  Dilip Nathwani, Christopher Conlon  Clinical.
Localized Mycobacterium avium complex infection in a patient on HAART
CMI readers' survey Clinical Microbiology and Infection
The future of diagnostic bacteriology
Vincent Calvez, Marc Grandadam  Clinical Microbiology and Infection 
Presentation transcript:

Evaluation of the effect of interleukin-10 on the multiplication of Mycobacterium avium complex in human macrophages and in C57BL/6 mice  Hilte F. Geerdes-Fenge, Yves Cohen, Christian Perronne, Guylène Bertrand, Claude Carbon  Clinical Microbiology and Infection  Volume 5, Issue 9, Pages 560-566 (September 1999) DOI: 10.1111/j.1469-0691.1999.tb00435.x Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 CFU/g of spleen of IL-10-treated mice and controls in C57BL/6 mice infected with 102 or 103 CFU of MAC (mean of four mice at each time point±SD). Clinical Microbiology and Infection 1999 5, 560-566DOI: (10.1111/j.1469-0691.1999.tb00435.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 CFU/g of spleen of C57BL/6 mice infected with 107 CFU of MAC after daily treatment with IL-10, cyclosporin A, or prednisolone (mean of four mice at each time point±SD). Clinical Microbiology and Infection 1999 5, 560-566DOI: (10.1111/j.1469-0691.1999.tb00435.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.